Allos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008

  
    
  
  
    
      Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it will 
      report 2008 first quarter financial results on Wednesday, May 7, 2008, 
      before the U.S. financial markets open.
    
    
      Paul L. Berns, President and Chief Executive Officer, and other members 
      of Allos' senior management will provide a company update and discuss 
      results via webcast and conference call on Wednesday, May 7, 2008 at 
      8:30 AM ET. The webcast of this call will be available from the homepage 
      and the investors/media section of the Company's website, www.allos.com, 
      and will be archived for 30 days. Alternatively, callers may participate 
      in the conference call by dialing 800-762-8779 (domestic) or 
      480-248-5081 (international). Webcast and telephone replays of the 
      conference call will be available approximately two hours after the 
      completion of the call through Friday, May 16, 2008. Callers can access 
      the replay by dialing 800-406-7325 (domestic) or 303-590-3030 
      (international). The passcode is 3865346.
    
    
      About Allos Therapeutics
    
    
      Allos Therapeutics is a biopharmaceutical company focused on developing 
      and commercializing small molecule therapeutics for the treatment of 
      cancer. The Company's lead product candidate, PDX (pralatrexate), is a 
      novel antifolate currently under evaluation in a pivotal Phase 2 
      (PROPEL) trial in patients with relapsed or refractory peripheral T-cell 
      lymphoma. The PROPEL trial is being conducted under an agreement reached 
      with the U.S. Food and Drug Administration under its special protocol 
      assessment, or SPA, process. The Company is also investigating PDX in 
      patients with non-small cell lung cancer and a range of lymphoma 
      sub-types. The Company's other product candidate is RH1, a targeted 
      chemotherapeutic agent currently being evaluated in a Phase 1 trial in 
      patients with advanced solid tumors or non-Hodgkin’s 
      Lymphoma (NHL). For additional information, please visit the Company’s 
      website at www.allos.com.
    
    
      Safe Harbor Statement
    
    
      The 2008 first quarter results press release and conference call will 
      contain forward-looking statements that involve significant risks and 
      uncertainties. Additional information concerning these forward-looking 
      statements and other factors that may cause actual results to differ 
      materially from those anticipated in the forward-looking statements is 
      contained in the "Risk Factors" section of the Company's Annual Report 
      on Form 10-K for the year ended December 31, 2007 and in the Company's 
      other periodic reports and filings with the Securities and Exchange 
      Commission. The Company cautions investors not to place undue reliance 
      on the forward-looking statements contained in the press release or the 
      conference call. All forward-looking statements are based on information 
      currently available to the Company on the date thereof, and the Company 
      undertakes no obligation to revise or update these forward-looking 
      statements to reflect events or circumstances after the date of this 
      presentation, except as required by law.